Glipizide extended-release tablets are recommended to be taken orally and need to be swallowed whole, the dosage varies from person to person, generally the recommended starting dose is 5mg/day, once a day, 30 minutes before breakfast. As a glucose-lowering drug needs to be taken under the guidance of a medical professional. Glipizide extended-release tablets can promote pancreatic β-cell secretion of insulin, enhance the effect of insulin on target tissues; can also stimulate pancreatic α-cells so that glucagon secretion is inhibited, but also inhibit the decomposition of hepatic glycogen, and promote the role of muscle utilization and consumption of glucose. It is suitable for patients with mild or severe type 2 diabetes mellitus that cannot be controlled satisfactorily by diet therapy alone. Contraindications: hypersensitivity to the ingredients of glipizide extended-release tablets; for clearly diagnosed type 1 diabetes mellitus; diabetes mellitus patients with ketoacidosis, coma, severe burns, infections, traumas and major surgery and other stressful situations; hepatic and renal insufficiency; leukopenia. Precautions: the more common adverse reactions are gastrointestinal symptoms, such as nausea, epigastric distension; skin allergies; occasional hypoglycemia, especially in the elderly and frail, over-active, irregular eating, alcohol consumption or liver function impairment; when adverse reactions should be promptly seek medical attention and adjust the drug regimen. Glipizide extended-release tablets should be used in accordance with medical advice, regular measurement of blood glucose, urine sugar, if hypoglycemic symptoms, such as headache, excitement, insomnia, tremor and profuse sweating should be promptly seek medical attention.